472 related articles for article (PubMed ID: 22443408)
1. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
[TBL] [Abstract][Full Text] [Related]
2. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
3. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
Maselli DJ; Singh H; Diaz J; Peters JI
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
[TBL] [Abstract][Full Text] [Related]
6. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
8. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in patients with severe asthma: the XCLUSIVE study.
Schumann C; Kropf C; Wibmer T; Rüdiger S; Stoiber KM; Thielen A; Rottbauer W; Kroegel C
Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
[TBL] [Abstract][Full Text] [Related]
10. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
11. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in the treatment of asthma.
Tan R; Corren J
Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
[TBL] [Abstract][Full Text] [Related]
13. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
15. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.
de Llano LP; Vennera Mdel C; Álvarez FJ; Medina JF; Borderías L; Pellicer C; González H; Gullón JA; Martínez-Moragón E; Sabadell C; Zamarro S; Picado C;
J Asthma; 2013 Apr; 50(3):296-301. PubMed ID: 23350994
[TBL] [Abstract][Full Text] [Related]
16. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
18. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of omalizumab in non-allergic severe asthma.
Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]